ODC mRNA as a prognostic factor for predicting recurrence in meningiomas

A. Klekner, G. Röhn, G. Schillinger, R. Schröder, N. Klug, R. I. Ernestus

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

In proliferating neoplastic cells, activity of the enzyme ornithine decarboxylase (ODC) increases. Among other brain tumors, ODC activation could also be observed in meningiomas. In the present study, we have investigated ODC gene expression in primary and recurrent meningiomas at the transcriptional level. ODC mRNA (messenger ribonucleic acid), ODC activity, number of mitoses, and Ki-67 index as a marker for nuclear proliferation were quantified in three different groups of meningiomas: tumors without recurrence in a 8.4 years median follow-up period, tumors with recurrence within a median follow-up of 3.0 years, and their corresponding recurrent tumors. ODC mRNA level was significantly higher in meningiomas with later recurrence as compared to meningiomas without recurrence (p ≤ 0.01), whereas it declined in the recurrences of the second group (p ≤ 0.001). In contrast, ODC activity showed no difference between the two groups of primary tumors, but a significant increase of enzyme activity could be observed in the recurrences as compared to the corresponding primary tumors (p ≤ 0.001). Likewise, an increase of the Ki-67 index could be detected in the recurrent group (p ≤ 0.001). These results suggest that ODC mRNA may represent a prognostic factor for predicting recurrence in meningiomas.

Original languageEnglish
Pages (from-to)67-75
Number of pages9
JournalJournal of Neuro-Oncology
Volume53
Issue number1
DOIs
Publication statusPublished - 2001

Fingerprint

Ornithine Decarboxylase
Meningioma
RNA
Recurrence
Neoplasms
Enzymes
Mitosis
Brain Neoplasms
Gene Expression

Keywords

  • Ki-67
  • Meningiomas
  • Mitoses
  • mRNA
  • Ornithine decarboxylase (ODC)
  • Prognosis
  • Recurrence

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neuroscience(all)

Cite this

Klekner, A., Röhn, G., Schillinger, G., Schröder, R., Klug, N., & Ernestus, R. I. (2001). ODC mRNA as a prognostic factor for predicting recurrence in meningiomas. Journal of Neuro-Oncology, 53(1), 67-75. https://doi.org/10.1023/A:1011878928318

ODC mRNA as a prognostic factor for predicting recurrence in meningiomas. / Klekner, A.; Röhn, G.; Schillinger, G.; Schröder, R.; Klug, N.; Ernestus, R. I.

In: Journal of Neuro-Oncology, Vol. 53, No. 1, 2001, p. 67-75.

Research output: Contribution to journalArticle

Klekner, A, Röhn, G, Schillinger, G, Schröder, R, Klug, N & Ernestus, RI 2001, 'ODC mRNA as a prognostic factor for predicting recurrence in meningiomas', Journal of Neuro-Oncology, vol. 53, no. 1, pp. 67-75. https://doi.org/10.1023/A:1011878928318
Klekner, A. ; Röhn, G. ; Schillinger, G. ; Schröder, R. ; Klug, N. ; Ernestus, R. I. / ODC mRNA as a prognostic factor for predicting recurrence in meningiomas. In: Journal of Neuro-Oncology. 2001 ; Vol. 53, No. 1. pp. 67-75.
@article{a3cdb95ac22b4d479bb540cf8b6bdca1,
title = "ODC mRNA as a prognostic factor for predicting recurrence in meningiomas",
abstract = "In proliferating neoplastic cells, activity of the enzyme ornithine decarboxylase (ODC) increases. Among other brain tumors, ODC activation could also be observed in meningiomas. In the present study, we have investigated ODC gene expression in primary and recurrent meningiomas at the transcriptional level. ODC mRNA (messenger ribonucleic acid), ODC activity, number of mitoses, and Ki-67 index as a marker for nuclear proliferation were quantified in three different groups of meningiomas: tumors without recurrence in a 8.4 years median follow-up period, tumors with recurrence within a median follow-up of 3.0 years, and their corresponding recurrent tumors. ODC mRNA level was significantly higher in meningiomas with later recurrence as compared to meningiomas without recurrence (p ≤ 0.01), whereas it declined in the recurrences of the second group (p ≤ 0.001). In contrast, ODC activity showed no difference between the two groups of primary tumors, but a significant increase of enzyme activity could be observed in the recurrences as compared to the corresponding primary tumors (p ≤ 0.001). Likewise, an increase of the Ki-67 index could be detected in the recurrent group (p ≤ 0.001). These results suggest that ODC mRNA may represent a prognostic factor for predicting recurrence in meningiomas.",
keywords = "Ki-67, Meningiomas, Mitoses, mRNA, Ornithine decarboxylase (ODC), Prognosis, Recurrence",
author = "A. Klekner and G. R{\"o}hn and G. Schillinger and R. Schr{\"o}der and N. Klug and Ernestus, {R. I.}",
year = "2001",
doi = "10.1023/A:1011878928318",
language = "English",
volume = "53",
pages = "67--75",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "1",

}

TY - JOUR

T1 - ODC mRNA as a prognostic factor for predicting recurrence in meningiomas

AU - Klekner, A.

AU - Röhn, G.

AU - Schillinger, G.

AU - Schröder, R.

AU - Klug, N.

AU - Ernestus, R. I.

PY - 2001

Y1 - 2001

N2 - In proliferating neoplastic cells, activity of the enzyme ornithine decarboxylase (ODC) increases. Among other brain tumors, ODC activation could also be observed in meningiomas. In the present study, we have investigated ODC gene expression in primary and recurrent meningiomas at the transcriptional level. ODC mRNA (messenger ribonucleic acid), ODC activity, number of mitoses, and Ki-67 index as a marker for nuclear proliferation were quantified in three different groups of meningiomas: tumors without recurrence in a 8.4 years median follow-up period, tumors with recurrence within a median follow-up of 3.0 years, and their corresponding recurrent tumors. ODC mRNA level was significantly higher in meningiomas with later recurrence as compared to meningiomas without recurrence (p ≤ 0.01), whereas it declined in the recurrences of the second group (p ≤ 0.001). In contrast, ODC activity showed no difference between the two groups of primary tumors, but a significant increase of enzyme activity could be observed in the recurrences as compared to the corresponding primary tumors (p ≤ 0.001). Likewise, an increase of the Ki-67 index could be detected in the recurrent group (p ≤ 0.001). These results suggest that ODC mRNA may represent a prognostic factor for predicting recurrence in meningiomas.

AB - In proliferating neoplastic cells, activity of the enzyme ornithine decarboxylase (ODC) increases. Among other brain tumors, ODC activation could also be observed in meningiomas. In the present study, we have investigated ODC gene expression in primary and recurrent meningiomas at the transcriptional level. ODC mRNA (messenger ribonucleic acid), ODC activity, number of mitoses, and Ki-67 index as a marker for nuclear proliferation were quantified in three different groups of meningiomas: tumors without recurrence in a 8.4 years median follow-up period, tumors with recurrence within a median follow-up of 3.0 years, and their corresponding recurrent tumors. ODC mRNA level was significantly higher in meningiomas with later recurrence as compared to meningiomas without recurrence (p ≤ 0.01), whereas it declined in the recurrences of the second group (p ≤ 0.001). In contrast, ODC activity showed no difference between the two groups of primary tumors, but a significant increase of enzyme activity could be observed in the recurrences as compared to the corresponding primary tumors (p ≤ 0.001). Likewise, an increase of the Ki-67 index could be detected in the recurrent group (p ≤ 0.001). These results suggest that ODC mRNA may represent a prognostic factor for predicting recurrence in meningiomas.

KW - Ki-67

KW - Meningiomas

KW - Mitoses

KW - mRNA

KW - Ornithine decarboxylase (ODC)

KW - Prognosis

KW - Recurrence

UR - http://www.scopus.com/inward/record.url?scp=0034794193&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034794193&partnerID=8YFLogxK

U2 - 10.1023/A:1011878928318

DO - 10.1023/A:1011878928318

M3 - Article

VL - 53

SP - 67

EP - 75

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 1

ER -